Synovitis has an important role in the symptoms and progression of Osteoarthritis (OA).
Inflamed synovium has been associated with both increased symptoms and increased progression
in OA patients. Furthermore, synovitis observed during knee arthroscopy in our patients
undergoing arthroscopic partial meniscectomy (APM) was associated with worse symptoms while
adjusting for confounding factors.Therefore, a better understanding of synovitis as a
predictor of outcome after APM and as a target for treatment is needed to improve outcomes in
this patient population.
Triamcinolone has been shown to decrease synovitis-associated outcomes in both animal and
human studies after anterior cruciate ligament (ACL) injury. In a porcine model of ACL
injury, treatment with triamcinolone resulted in decreased formation of synovitis-related
collagen breakdown products as well as decreased cellularity of the synovium.And in a trial
of triamcinolone injected after ACL injury, similar findings of decreased C-telopeptide of
type II collagen (CTX-II), associated with collagen type II breakdown, was found in knees
administered triamcinolone compared to placebo controls.